Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of 67 years at
presentation. In the past, only a third of older patients (defined as individuals older than 60 …

Management of AML involves choosing between purely palliative care, standard therapy
and investigational therapy (“clinical trial”). Even most older patients likely benefit from …

Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older.
We examined patient characteristics, treatment patterns, and survival among elderly patients …

Abstract Purpose of Review Treatment of elderly patients with acute myeloid leukemia is a
known challenge for hematologists due to patient diversity, heterogeneous disease biology …

With a few subgroups as exceptions, such as younger patients with more favorable genetic
disease, improvement in the treatment of acute myeloid leukemia has been slow. There is a …

Evidence suggest that even patients aged 70 or above benefit from specific AML therapy.
The fundamental decision in AML then becomes whether to recommend standard or …

Acute myeloid leukemia (AML) in older patients presents a notable therapeutic challenge to
the clinical hematologist. The clinical biology of AML among patients is highly …

Background Acute myeloid leukemia is the second most common leukemia among United
States adults with a median age of 69 years. We investigated recent clinical practices related …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …